Overview of the Vaccinia Virus Expression System

Bernard Moss1, Patricia L. Earl1

1 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland
Publication Name:  Current Protocols in Protein Science
Unit Number:  Unit 5.11
DOI:  10.1002/0471140864.ps0511s13
Online Posting Date:  May, 2001
GO TO THE FULL TEXT: PDF or HTML at Wiley Online Library

Abstract

The vaccinia virus expression system differs from others in that transcription occurs in the cytoplasm of mammalian cells rather than in the nucleus. As a vector, vaccinia virus has a number of useful characteristics, including a capacity that permits cloning large fragments of foreign DNA (20+ kbp) with retention of infectivity, a wide host range, a relatively high level of protein synthesis, and “appropriate” transport, secretion, processing, and posttranslational modifications as dictated by the primary structure of the expressed protein and the cell type used. This overview discusses the life cycle of the vaccinia virus along with effects of vaccinia infection. The vaccinia vector expression system is described along with specific steps for expressing genes using these vectors. Important safety considerations are also presented.

     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Table of Contents

  • Vaccinia Replication Cycle
  • Effects of Vaccinia Infection
  • Vaccinia Vector Expression System
  • Steps for Expression of Genes Using Vaccinia Vectors
  • Safety Precautions for Using Vaccinia
  • Figures
     
 
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Materials

GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library

Figures

Videos

Literature Cited

Literature Cited
   Bennink, J.R. and Yewdell, J.W. 1990. Recombinant vaccinia viruses as vectors for studying T lymphocyte specificity and function. Curr. Topics Microbiol. Immunol. 163:153‐184.
   Baxby, D. 1989. Smallpox vaccination for investigators. Lancet 2:919.
   Earl, P.L., Hügin, A.W., and Moss, B. 1990. Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus. J. Virol. 64:2448‐2451.
   Mackett, M., Smith, G.L., and Moss, B. 1982. Vaccinia virus: A selectable eukaryotic cloning and expression vector. Proc. Natl. Acad. Sci. U.S.A. 79:7415‐7419.
   Moss, B. 1996a. Poxviridae: The viruses and their replication. In Virology (B.N. Fields D.M. Knipe and P.M. Howley eds.) pp. 2637‐2671. Raven Press, New York.
   Panicali, D. and Paoletti, E. 1982. Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc. Natl. Acad. Sci. U.S.A. 79:4927‐4931.
   Richmond, J.Y. and McKinney, R.W. 1993. Biosafety in Microbiological and Biomedical Laboratories 3rd ed. U.S.Government Printing Office, Washington, D.C.
   Tartaglia, J., Perkus, M.E., Taylor, J., Norton, E.K., Audonnet, J.C., Cox, W.I., Davis, S.W., Vanderhoeven, J., Meignier, B., Riviere, M., Languet, B., and Paoletti, E. 1992. NYVAC–A highly attenuated strain of vaccinia virus. Virology 188:217‐232.
   Wenzel, R.P. and Nettelman, M.D. 1989. Smallpox vaccination for investigators using vaccinia recombinants. Lancet 2:630‐631.
Key References
   Johnson, G.P., Goebel, S.J., and Paoletti, E. 1993. An update on the vaccinia virus genome. Virology 196:381‐401.
   Moss, B. 1996b. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U.S.A. 93:11341‐11348.
GO TO THE FULL PROTOCOL:
PDF or HTML at Wiley Online Library